Gene and Stem Cell Therapies Make Strong Showing at ALS/MND Meeting
More than 800 researchers, clinicians, and patients with ALS gathered in balmy Orlando, Florida, on December 11-13, for the 26th International Symposium on ALS/MND. Read more here.…
Trial News & Events
Pauses and reversals ‘not uncommon’ in ALS progression
Patients with amyotrophic lateral sclerosis (ALS) often have periods of stable disease, with some even experiencing brief improvements, shows analysis of the PRO-ACT database. Read more here.…
MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-16
Presented at the 26th International Symposium on ALS/MND in Orlando, FL. Read more here.…
Treeway announces positive data from two separate Phase I TW001 clinical trials
Successful dose and confirmatory study solid platform for phase II/III trial in ALS patients. Read more here.…
Treeway to collaborate on developing AAV5-GDNF gene therapy for ALS
Treeway is pleased to announce a collaboration with the Cedars-‐Sinai Board of Governors Regenerative Medicine Institute for the development of AAV5-‐GDNF (TW002) gene therapy for ALS. Read more here.…
Answer ALS + NFL Game-Changing Moments
"The NFL has had 1000s of game changers, ALS only needs 1." Watch here.…
Tar Heel: Duke Dr. Richard Bedlack collecting new ideas to fight ALS
Bedlack founded and directs Duke University’s ALS Clinic, which takes an unusual interdisciplinary approach to helping ease the suffering and extend the lives of patients with this fatal disease. Read more here.…
FDA Approves a New Clinical Protocol to Evaluate the Effects of MN-166 (ibudilast) on a Biomarker of
(November 9, 2015) This is an Open-Label, Proof-of-Mechanism, Phase 2a trial of ibudilast in ALS patients. Read more here.…
Federal funding secured for Barrow-TGen advanced technology study of Amyotrophic Lateral Sclerosis
Multi-year study of patients seeks biomarkers that can provide early detection and progression of Lou Gehrig's disease. Read more here.…
BrainStorm Announces Treatment of Final Patient in US Multicenter Double Blinded Phase 2 ALS Trial
The study was designed to evaluate the safety and efficacy of transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors. Read more here.…